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BODIPY-Labeled Cyclobutanes by Secondary C(sp3)─H 
Arylations for Live-Cell Imaging 
Matteo Virelli,[a, b] † Wei Wang,[a] † Rositha Kuniyil,[a] Jun Wu,[a] Giuseppe Zanoni,[b] Antonio Fernandez,[c] 
Jamie Scott,[c] Marc Vendrell[c] and Lutz Ackermann*[a,b,d] 
 
Abstract: Arylated cyclobutanes were accessed by a versatile 
palladium-catalyzed secondary C(sp3)–H activations exploiting 
chelation assistance by modular triazoles. The C−H arylation led to 
cyclobutane natural product derivatives in a highly regioselective 
fashion, setting the stage for the rapid access to novel fluorogenic 
BODIPY-labeled probes for live-cell imaging.  
Cyclobutanes represent important building blocks for complex 
natural molecules with relevant biological activities, and found as 
a core motifs in several natural products (Scheme 1a).[1] For 
instance, pipercyclobutanamides, piperchabamides, nigramides, 
and dipiperamides are tetrasubstituted cyclobutanes of relevance 
to traditional medicines.[2] Specifically, pipercyclobutanamide A 
and dipiperamide E belong to a family of molecules that 
selectively inhibit CYP2D6 and CYP3A4, the two main 
cytochrome P450 isoenzymes responsible for drug metabolism.[3] 
In nature, the strained cyclobutane ring is constructed via the 
coupling of the monomeric olefins. However, this approach is not 
applicable in the laboratory due to the by-products originated from 
the [2+2] photocycloaddition strategy.[4] In this context, C−H 
activations can be considered as an unconventional alternative to 
classical approaches, such as the intermolecular 
photocycloaddition to access unsymmetrical cyclobutane 
derivatives. Despite undisputable progress,[5] the functionalization 
of inert C(sp3)–H bond, the most ubiquitous chemical bonds in 
nature, continues to be challenging. Hence, the formation of C−C 
bonds from unactivated secondary C(sp3)–H bonds continues to 
be rare and most of the reported examples are limited to specific 
substrates or favored by entropically-biased intramolecular 
reactions.[6] Notable progress has been witnessed by palladium-
catalyzed C(sp3)‒H activations as reported by Corey,[7] 
Kazmaier,[8] Chen,[9] Daugulis,[10] Shi,[11] Yu[12] and Ackermann,[13] 
among others[14] using auxiliaries such as 8-aminoquinoline[15] or 
picolinamide[16] bidentate directing groups as well as perfluoroaryl 
containing directing groups.[17] These approaches offer unique 
opportunities for overcoming the longstanding challenge 
constituted by the stereocontrolled synthesis of structurally 
complex cyclobutanes. Baran indicated the power of 
palladium(II/IV) catalysis towards methylene C−H activation.[18] 
As part of our program on sustainable CH activations,[19] we have 
now devised the first example of triazole-assisted CH 
functionalization of cyclobutanes (Scheme 1b).[20] Triazole-based 
TAM groups can be easily accessed under mild reaction 
conditions in a highly modular fashion via 1,3-dipolar Huisgens 
cycloaddition reaction.[21] Moreover, isosteric triazoles have been 
frequently utilized in bioactive peptidomimetics as powerful amide 
surrogates.[22] Our strategy led not only to arylated cyclobutanes 
with high regio- and stereo-selectivity. Indeed, cyclobutane 
BODIPYs[23] were prepared for the first time as effective 
biorelevant molecules for live-cell imaging studies. Notable 
features of our approach include 1) efficient triazole-assisted 
secondary C(sp3)–H cyclobutane arylations, 2) access to natural 
product derivatives, 3) transformative fluorophore labeling in a 
stereo- and regioselective fashion, and 4) novel cyclobutane-
BODIPY molecules for fluorescence-based live-cell imaging. 
 
Scheme 1. Secondary C(sp3)–H arylation for BODIPY-cyclobutanes. 
We initiated our studies by probing various reaction parameters 
for the envisioned C(sp3)–H arylation of cyclobutane 1a (see 
Supporting Information). After considerable preliminary 
experimentation, we identified o-xylene as the optimal solvent, 
AgOAc and Pd(TFA)2 as the base and catalyst of choice (Scheme 
2). Thereby, the desired secondary C(sp3)–H functionalization 
occurred with high catalytic efficacy and complete 
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Scheme 2. Optimized triazole-assisted secondary C(sp3)–H arylation. 
The diarylated compounds 2 were obtained selectively as the 
all-cis-diastereomers when employing an excess of the 
electrophilic aryl iodides. Encouraged by these results, we tested 
the versatility of the optimized catalyst (Scheme 2). The C(sp3)–
H arylation proved to be widely applicable and was found to be 
compatible with valuable electrophilic functional groups, such as 
fluoro, chloro, amide and ester substituents (2h, 2i, 2k, 2l, 2o, 2s, 
2t, 2w). Interestingly, mono-arylated products 2x, 2y were 
selectively obtained when five- or six-membered cycloalkanes 
were employed, again featuring complete cis-selectivity.  
 
Scheme 3. Scope of secondary C(sp3)–H arylation. 
The mechanism of the activation of C(sp3)–H bond of 
cyclobutane was studied by means of density functional theory 
(DFT) calculations at the PW6B95-D3(BJ)/def2-TZVP+COSMO 
(o-xylene)//TPSS-D3(BJ)/def2-TZVP level of theory (Figure 1). 
Our findings highlight a facile formation of the palladacycle im4 
by carboxylate-assisted[24] secondary C(sp3)–H activation.  
 
Figure 1. Computed relative Gibbs free energy profile in kcal mol−1 for the 
secondary C(sp3)–H activation at the PW6B95-D3(BJ)/def2-TZVP+COSMO 
(o-xylene)//TPSS-D3(BJ)/def2-TZVP level of theory. Non-relevant hydrogen 
atoms were omitted for clarity in the transition state geometries.  
Intrigued by the unique potential of BODIPYs[25] as 
biocompatible fluorescent probes, we explored BODIPY labeling 
by testing different BODIPYs in our secondary C(sp3)–H 
activation process (Scheme 4). We were thus pleased to discover 
the unprecedented BODIPY fluorescence labeling on the desired 
cyclobutane with cis stereochemistry to furnish the mono 
functionalized BODIPY cyclobutanecarboxamide 3.  
 
 
Scheme 4. BODIPY labeling of cyclobutanes by secondary C(sp3)–H activation. 





Next, we applied our strategy to the cyclobutane-1-carboxylate 
1d, further substantiating the robustness towards natural product 
analogs (Scheme 5). These studies also enabled the preparation 
of BODIPY labeled cyclobutane-1-carboxylate 4c, as an 
unprecedented fluorescent core of natural product derivatives, 
such as piperarborenine B, Santiaguine and Piplartine.  
 
Scheme 5. Cyclobutanes-1-carboxylate derivatives by secondary C(sp3)–H 
activation. 
Considering that cyclobutane natural products display 
significant anticancer activity, we evaluated the biological activity 
of the non-fluorescent cyclobutane 4a and a BODIPY fluorescent 
analogue 3a. Cell viability measurements in human cervical 
cancer cells indicated similar trends for both on their dose-
dependent cytotoxicity (Figure 2), which suggests that BODIPY-
labeled cyclobutanes may retain some of the properties on the 
unlabeled cores. 
 
Figure 2. Anticancer activity assays. Cell viability after incubation with different 
concentrations of compounds 3a and 4a were measured, using cells incubated 
with only DMSO as a positive control for cell death. Values are represented as 
means (n=3) and error bars as s.d.  
 
To further modify the BODIPY labeled cyclobutane core, the 
mono BODIPY-labeled compound 3d was transformed into the bi-
functionalized products 5a and 5b in an iterative C–H activation 
fashion (Scheme 6). In particular, the double C–H activation led 
to unsymmetrical cyclobutanes containing one aryl moiety and 
one red fluorescent BODIPY dye, featuring mimics of biorelevant 
natural products. Indeed, these compounds are structural mimics 
of the naturally occurring cyclobutanecarboxamide 
piperarborenine B, highlighting an additional fluorescent BODIPY 
scaffold. 
 
Scheme 6. Two-fold C(sp3)–H BODIPY labeling and arylation of cyclobutanes. 
Given the novelty of the cyclobutane-BODIPY hybrids, we 
analyzed their spectral and biological properties for live-cell 
imaging. The tetramethyl BODIPY derivative 3a emitted in the 
green visible range (exc.: 495 nm, em.: 510 nm), whereas the 
extended p-methoxyaryl derivative 3d showed bright 
fluorescence emission in the red region (exc.: 580 nm, em.: 620 
nm). These results indicate that cyclobutane labeling does not 
affect the excitation and emission profiles of conventional 
BODIPY structures. Next, we analyzed the emission in different 
organic solvents and the environmentally-sensitive properties of 
compounds 3a and 3d, and compared them to a tetramethyl 
BODIPY-aryl (BA) structure devoid of the cyclobutane ring. We 
measured their fluorescence emission both in aqueous buffer in 
hydrophobic liposome suspensions to observe that compounds 
3a and 3d showed a stronger fluorogenic behavior than BA, which 
highlights a notable increase in environmental sensitivity due to 
the cyclobutane motif (Figures 3 and S3 and Table S8). Next, we 
used compounds 3a and 3d for fluorescence imaging of live-cell 
RAW264.7 macrophages. Both green and red cyclobutane-
BODIPY derivatives were permeable and brightly stained 
macrophages, to a similar extent than BA when used at 
nanomolar concentrations (Figure S2). We also acquired high 
magnification fluorescence images of RAW264.7 macrophages 
after incubation with compounds 3a and 3d and commercial the 
intracellular markers Hoechst 33342-nuclei, LysoTracker-
lysosomes as well as MitoTracker-mitochondria (Figure 3). From 
these experiments, we can conclude that both BODIPY labeled 





cyclobutanes localize in the cytoplasm, but do not preferentially 
accumulate in the lysosomes or in the mitochondria.    
 
 
Figure 3. a) Fluorescence emission spectra of compounds 3a and 3d. b) 
Fluorogenic response of compounds 3a, 3d and BODIPY-aryl (BA) after 
incubation in liposome suspensions (grey bars) and in phosphate buffer saline 
(black bars). c) Fluorescence confocal microscopy of live RAW264.7 
macrophage cells after treatment with compound 3a (green, top panels) and 
compound 3d (red, bottom panels), both at 250 nM. Cells were counterstained 
with Hoechst 33342 (blue) for nuclei (N), Lysotrackers (red in top panel, green 
in bottom panel) for lysosomes (L), and MitoTrackers (red in top panel, green in 
bottom panel) for mitochondria (M). Scale bars: 10 m.  
In conclusion, we have reported on the unprecedented 
secondary C(sp3)–H arylation by TAM assistance to provide 
efficient access to functionalized cyclobutane natural product 
analogs. The robustness of our secondary C(sp3)–H activation 
was reflected by an excellent functional group tolerance and 
ample substrate scope. The synthetic utility of our strategy was 
further validated by preparing the first cyclobutane-BODIPY 
derivatives, which paves the way for new approaches in the 
chemical derivatization of natural products with fluorescent 
labels.[26]   
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